Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 301: Sotorasib + Panitumumab + FOLFIRI vs FOLFIRI ± Bevacizumab in Treatment‑naïve Metastatic KRAS p.G12C Colorectal Cancer
2022-502352-31-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 34
01
Overview
Phase 3, randomised, open-label trial of sotorasib in colorectal cancer (CRC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival (PFS) by BICR. Planned start Jul 2024; status: authorised.
02
Drugs
sotorasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-502352-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502352-31-00.